SAN FRANCISCO, Oct. 24 – Millennium Pharmaceuticals entered a four-year R&D and volume discount supply agreement with Affymetrix, the companies announced Wednesday.
The deal includes co-development of gene expression array processes and applications for drug discovery and development, including next generation GeneChip technology applications.
Millennium, based in Cambridge, Mass., will transition its microarray use to Affymetrix’s GeneChip technology over the next year. Santa Clara-based Affymetrix will give Millennium preferred access and pricing to its gene expression platform, according to the companies.
Financial details of the agreement were not disclosed.
“Through this collaboration we will accelerate the evolution and use of our technology in drug development and health care,” said Robert Lipshutz, vice president of corporate development and licensing at Affymetrix. “We plan to capture improvements to enhance our commercial offering.”